Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab intravenous plus intra-arterial administration for recurrent high-grade glioma
ChiCTR2000030654Phase 3Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of bevacizumab in glioma (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: progression-free survival and overall survival. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2000030654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030654.